Speakers
Luigi Angelillo, Director, Market Access EMEA, Argenx
Ad Antonisse, Director Market Access & External Affairs, AstraZeneca BV
Fausto Artico, Global R&D Tech Head of Innovation & Data Science, GSK
Marnix Artz, Head of Patient Access, Pricing & Public Affairs, Netherlands, Merck Group
Cecilie Astrup, Health economist, Amgros I/S
Yumi Asukai, Senior Director, Gilead Sciences Ltd
Marta Baldrighi, Policy and Science Officer, Medicines for Europe
Giovanna Barcelos, HEOR RWE Senior Manager, Europe & GCC, Global Blood Therapeutics
Dorothee Bartels, Global Head RWE, UCB
Alexander Bastian, VP Value & Market Access, A.M. Pharma
Tomer Ben Zaken, Regional Business Operation Lead, Takeda
Nadia Benhadi, Eu Market Access And Pricing Director, GlaxoSmithKline
Jesper Bjerggren, European Market Access Lead Respiratory/Digital Health, Teva Pharmaceuticals
Marie-sharmila Blandino, Marketing Manager, Amgen
Axel Boehnke, Director Market Access EU North, PTC Therapeutics
Amanda Bok, Chief Executive Officer, European Haemophilia Consortium
thomas bols, head of government affairs and patient advocacy, EMEA & APAC, PTC Therapeutics
Vidya Breeveld, Founder, Transmineo
Rob Burley, Director Of Campaigns, Care And Support, The Muscular Dystrophy U.K.
Astrid Buys, Global Head of Tenders & Pricing, Bavarian Nordic A/S
Sandro Cesaro, Head, Market Access and Innovative Value Strategies, Oncology Europe, AstraZeneca
Mata Charokopou, Head of Payer value Strategy, UCB
Helene Chevrou-Severac, HEOR RWE Centre of Excellence Head, International & Japan, Alexion
José Luis Sánchez Chorro, Market Access Director Spain and Portugal, Jazz Pharmaceuticals
Sally Chung, VP, Head of Market Access & Pricing Europe, GSK
Friso Coerts, Market Access & HTA Manager, Pfizer
Jean-Philippe Combal, Co-Founder And Chief Executive Officer, Vivet Therapeutics
Stephen Connell, Director Payer Insights & Access, Pfizer Ltd
Rossella Di Bidino, HTA expert, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Anna Dickinson, Policy Manager, Public Policy Projects
Toon Digneffe, Head Public Affairs & Public Policy, Europe & Cana, Takeda
Marcus Droege, Vice President, Global Value & Market Access, Passage Bio
Gilles Ducorroy, Global Head of RWE Services, Novartis
Michael Ermisch, Specialist, Department Of Pharmaceuticals, G.K.V. Spitzenverband
Frederic Ernst, Head of Market Access for Europe, Santen
Gina Ewy, Head Global Market Access, Hansa Biopharma
Marina Faiella, Director of Hematology Market Access Europe, Beigene
Stefaan Fiers, Head of Corporate Communication, Public Affairs & Patient Advocacy, Belgium, Takeda
Graham Foxon, Managing Director, remap consulting
Stefan Franzen, Director, Medical & Payer Evidence Statistics, AstraZeneca
Pat Garcia-Gonzalez, Chief Executive Officer, THE MAX FOUNDATION
Philippe Ghyssels, VP Corporate and Global Public Affairs, ipsen
Christoph Glaetzer, Chief Global Value and Access Officer, The Janssen Pharmaceutical Companies of Johnson & Johnson
Denise Globe, Head Global Health Economics and Outcomes Research Center of Excellence, Gilead Sciences
Josie Godfrey, Co-Founder and Chief Executive Officer, Realise Advocacy
Wim Goettsch, Associate Professor of HTA, Utrecht Centre for Pharmaceutical Policy and Regulation
Alicia Granados, Head, Global Rare Diseases Scientific Advocacy, SANOFI
Laura Guarga, Consultant of Pharmacoeconomic Department, CatSalut
Sondes Hamida, Head of Medicines Assessment Department, Tunisian National Health Insurance Fund
Gunter Harms, Senior Market Access Director, Novartis Gene Therapies
Tanja Heidbrede, Head RWE Central EU, UCB
Giorgio Iotti, Head Of Program Leadership And Control, Rare Disease Unit, Chiesi Farmaceutici SpA
Amy Israel, Vice President and Global Head, Oncology Policy & Healthcare Systems, Novartis
Saira Jan, Vice-President & Chief Pharmacy Officer, Blue Cross Blue Shield of New Jersey
Pall Jonsson, Programme director for Data, Nice
Gomathi Kaliappan, Health Systems Strategy Leader - Global Access, Roche
Lisette Kaskens, Senior Global Market Access Manager, Advanced Accelerator applications
Nadia Kaskure, Value Strategy Lead, novo nordisk
Linda klein Holkenborg, Medical Advisor, CZ
Diane Kleinermans, President of the Commission of Drugs Reimbursement, Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV)
Jolanda Koenders, Head of Patient Value and Access, Takeda Nederland
Augusta Elizabeth Koroma, Chief Executive Officer, Sickle cell Intervention U.K
Aleksandra Krygiel-Nael, Head of Government Affairs and Policy, Medical Devices, Johnson & Johnson
Maria Kubin, Vice President of Global Market Access, Bayer Healthcare Ag
Hannah Kurth, Global Value and Access Lead, Horizon Therapeutics
Timothy Lenehan, CVP Global Evidence, Pricing and Access, Novo Nordisk
Giovanny Leon, Pricing & Access Regional Director - LatAm & Canada, Novartis AG
Friedhelm Leverkus, Director Health Technology Assessment And Outcomes Research, Pfizer
Gavin Lewis, Vice President Global Head of Market Access, Amgen
Herve Lilliu, Chief Executive Officer, Inbeeo
Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board, Government of Canada
James Maddocks, International Policy Advisor, NHS Confederation
Joerg Mahlich, Market Access and Government Affairs Lead, Miltenyi Biomedicine GmbH
Bart Malfait, Director Government Affairs & Market Access (BeLux), Astra Zeneca
Marco Marchetti, Director of Health Technology Assessment Unit, National Agency for Regional Care Services, Agenzia Nazionale per i Servizi Sanitari Regionali- Agenas
Marisca Marian, Market Access Strategy Leader, Bayer
Linda Mcnamara, Market Access Director, Kyowa Kirin GmbH
Rasha Mokaddem, Market Access Director, Johnson & Johnson
Paolo Morgese, EU Director Market Access & Member Relations, Alliance for Regenerative Medicine
Tal Morginstin, Director, HTA division, Ministry of Health
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Andrew Olaye, Head of EMEA Market Access, Orchard Therapeutics Ltd
Melvin Olson, Global Head Integrated Evidence Strategy and Innovation, Novartis
Mario Ouwens, Group Director Medical & Payer Evidence Statistics, AstraZeneca
Sandra Paci, Global Market Access And Pricing Director, Argenx
Francis Pang, Senior Vice President, Global Market Access, Orchard Therapeutics
Elena Panitti, Global Head Real World Evidence Excellence, Novartis
Michela Pantaleoni, Head of Market Access Rare Diseases Europe & Emerg, Chiesi Global Rare Disease
Julien Patris, Director Market Access & Policy – Europe / Canada / MEA (CEMEA), Alnylam
Marco Penske, Head Of Market Access And Health Care Affairs, Boehringer-Ingelheim
Lara Pippo, Head Of Market Access, Italy, CSL Behring
Anke Pisters-van Roy, MD, CZ
Ana Plata, Head of Global Pricing Implementation BBU, AstraZeneca
Ludovica Polverino, Market Access Director, Daiichi Sankyo Development Ltd
Luis Prieto Rodriguez, Global Real-World Evidence Director, Novartis
Sonia Pulido, HTA Co-ordinator, Spanish Medicines Agency
Sreeram Ramagopalan, Global Head Real-World Evidence (Market Access), Roche
Nuno Prego Ramos, Chief Executive Officer, cellmabs
Marco Rauland, Vice President Global Market Access & Pricing - Strategic Planning, Merck Group
Laurene Redding, Head, Value, Access & Policy, Canada, Beigene
Peny Retsa, Market Access and External Relations Director, Abbvie
Sybille Riou, Global Market Access Manager, Miltenyi Biotec
Igor Rudychev, Vice President, Enterprise Analytics, Horizon
Sandrine Ruiz, Director Global Market Access and Pricing, Independent
Marcelo Sal, Head of Market Access and Pricing, South Cone of South America, PTC Therapeutics
Steve Sandor, Vice President of Market Access and Trade, Paratek Pharmaceuticals , Inc.
Sophie Schmitz, Managing Partner, Partners4Access
Michael Schroter, Co-Head Sustainable Healthcare Equity, HSBC
Ayman Semaan, Head of Market Access, Biologix
Maja Sercic, Policy & Science Manager, Medicines for Europe
Hans Severens, Scientific adviser, Severens HTA Consultancy
Navin Sewak, Global Market Access Director, ViiV Healthcare
Helen Stoop, Head of Tender Excellence & PDT Payer Value, Takeda
Teddy Sun, Evidence Generation Lead, Takeda
Jan Swiderski, Public Affairs & Advocacy Director, ipsen
Monika Szkultecka-Debek, Vice President, Qualitas Vitae Institute Foundation
Giovanni Tafuri, Director International Market Access and Policy, Apellis Pharmaceuticals
Peter Takacs, Global Business Operations, Miltenyi Biotec B.V. & Co. KG
Sam Taylor, Emerging Markets Strategic Pricing Lead, Pfizer
Ariella Toren, Director Of Medicine And Medical Technologies, Hmos Department, Israel - Ministry Of Health
Ilona Torontali, Global Head Pricing and Reimbursement, Roche
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Fipra
Andreas Uttenweiler, Head Patient Value Access & Public Affairs, Takeda Pharma AG
Bart Van Den Daele, Head of External Affairs – Director Market Access - Belux, Gilead Sciences
Goedele Van Haasteren, Staff Member, Swiss Federal Office of Public Health
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Medical Advisor, CZ
Kärt Veliste, Chief Specialist at Department of Medicines and Medical Devices, Haigekassa Estonia
Kalman Wijaya, Head of Market Access, Versantis
Lara J Wolfson, Executive Director and Head of Hta Statistics, Merck
Natasa Zibelnik, Global Head of Value, Access and Pricing, Eusa Pharma
Zinajda Zolic-Karlsson, Senior Advisor HTA and Reimbursement, Norwegian Medicines Agency
Zsombor Zrubka, Associate Professor - Department Of Health Economics, Obuda University
Get Involved
To Sponsor Or Exhibit
David Boore
david.boore@terrapinn.com
+44 20 8164 3052
To Speak
Francesca Wiggins
francesca.wiggins@terrapinn.com
Marketing Opportunities
Diana Cobzac
diana.cobzac@terrapinn.com
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events